

# Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Richard B. Lipton, MD, Patricia Pozo-Rosich, MD, PhD, Andrew M. Blumenfeld, MD, Ye Li, PhD, Lawrence Severt, MD, PhD, Jonathan T. Stokes, MBA, Lela Creutz, PhD, Pranav Gandhi, PhD, and David Dodick, MD

*Neurology*® 2023;100:e764-e777. doi:10.1212/WNL.0000000000201568

## Correspondence

Dr. Lipton  
richard.lipton@  
einsteinmed.edu

## Abstract

### Background and Objectives

The oral calcitonin gene-related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine.

### Methods

In this phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial (ADVANCE), adults with 4–14 migraine days per month received atogepant (10, 30, or 60 mg) once daily or placebo. Secondary endpoints included changes from baseline in Migraine-Specific Quality-of-Life Questionnaire (MSQ) version 2.1 Role Function–Restrictive (RFR) domain at week 12 and mean monthly Activity Impairment in Migraine–Diary (AIM-D) Performance of Daily Activities (PDA) and Physical Impairment (PI) domains across the 12-week treatment period. Exploratory endpoints included change in MSQ Role Function–Preventive (RFP) and Emotional Function (EF) domains; AIM-D total scores; and change in Headache Impact Test (HIT)–6 scores.

### Results

Of 910 participants randomized, 873 comprised the modified intent-to-treat population (atogepant: 10 mg [n = 214]; 30 mg [n = 223]; and 60 mg [n = 222]; placebo [n = 214]). All atogepant groups demonstrated significantly greater improvements vs placebo in MSQ RFR that exceeded minimum clinically meaningful between-group difference (3.2 points) at week 12 (least-square mean difference [LSMD] vs placebo: 10 mg [9.9]; 30 mg [10.1]; 60 mg [10.8]; all  $p < 0.0001$ ). LSMDs in monthly AIM-D PDA and PI scores across the 12-week treatment period improved significantly for the atogepant 30 (PDA:  $-2.54$ ;  $p = 0.0003$ ; PI:  $-1.99$ ; and  $p = 0.0011$ ) and 60 mg groups (PDA:  $-3.32$ ;  $p < 0.0001$ ; PI:  $-2.46$ ;  $p < 0.0001$ ), but not for the 10 mg group (PDA:  $-1.19$ ;  $p = 0.086$ ; PI:  $-1.08$ ;  $p = 0.074$ ). In exploratory analyses, atogepant 30 and 60 mg were associated with nominal improvements in MSQ RFP and EF domains, other AIM-D outcomes, and HIT-6 scores at the earliest time point (week 4) and throughout the 12-week treatment period. Results varied for atogepant 10 mg.

### Discussion

Atogepant 30 and 60 mg produced significant improvements in key patient-reported outcomes including MSQ-RFR scores and both AIM-D domains. Nominal improvements also occurred for other MSQ domains and HIT-6, reinforcing the beneficial effects of atogepant as a new treatment for migraine prevention.

## RELATED ARTICLE

### Editorial

Migraine—Not Just a Numbers Game: Aim to Improve Quality of Life  
Page 357

## MORE ONLINE

### Class of Evidence

Criteria for rating therapeutic and diagnostic studies

[NPublic.org/coe](https://npublic.org/coe)

From the Albert Einstein College of Medicine and the Montefiore Headache Center (R.B.L.), Bronx, NY; Headache Unit, Neurology Department (P.P.-R.), Vall d'Hebron University Hospital, Barcelona; Headache Research Group, VHIR (P.P.-R.), Universitat Autònoma de Barcelona, Barcelona, Spain; Headache Center of Southern California (A.M.B.), Carlsbad, CA; AbbVie (Y.L., L.S., J.T.S., P.G.), Madison, NJ; Peloton Advantage LLC, an OPEN Health Company (L.C.), Parsippany, NJ; and Department of Neurology (D.W.D.), Mayo Clinic, Scottsdale, AZ.

Go to [Neurology.org/N](https://Neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by AbbVie.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

## Glossary

**AIM-D** = Activity Impairment in Migraine–Diary; **CGRP** = calcitonin gene–related peptide; **CM** = chronic migraine; **eDiary** = electronic diary; **EF** = Emotional Function; **EM** = episodic migraine; **eTablet** = electronic tablet; **HA** = headache (day); **HIT-6** = Headache Impact Test–6; **FDA** = Food and Drug Administration; **HRQoL** = health-related quality of life; **ICHD-3** = *International Classification of Headache Disorders, third edition*; **LSMD** = least-square mean difference; **mAb** = monoclonal antibody; **MID** = minimally important difference; **mITT** = modified intent-to-treat; **MHD** = monthly headache day; **MMD** = monthly migraine days; **MMRM** = mixed models for repeated measure; **MSQv2.1** = Migraine-Specific Quality-of-Life Questionnaire version 2.1; **nHA** = nonheadache (day); **PDA** = performance of daily activities; **PI** = physical impairment; **PRO** = patient-reported outcome; **QD** = once daily; **RFP** = Role Function–Preventive; **RFR** = Role Function–Restrictive.

## Trial Registration Information

ClinicalTrials.gov NCT03777059. Submitted: December 13, 2018; First patient enrolled: December 14, 2018. [clinicaltrials.gov/ct2/show/NCT03777059](https://clinicaltrials.gov/ct2/show/NCT03777059).

## Classification of Evidence

This study provides Class II evidence that daily atogepant is associated with improvements in health-related quality-of-life measures in patients with 4–14 migraine days per month.

Migraine, a highly prevalent neurologic disease defined by recurrent attacks of headache pain and associated symptoms (e.g., aura, photophobia, nausea, and allodynia), is a leading cause of disease burden.<sup>1–5</sup> Migraine reduces the performance of daily activities, participation in social/leisure activities, physical/emotional functioning, and health-related quality of life (HRQoL), both during and between attacks.<sup>6–11</sup> Preventive migraine treatments aim to reduce the frequency, intensity, and duration of attacks and should reduce activity limitations and improve HRQoL.<sup>12,13</sup> Assessing the effect of migraine on HRQoL using patient-reported outcome (PRO) measures is important when evaluating preventive treatments.<sup>12–15</sup>

Atogepant is a recently approved oral, small-molecule, calcitonin gene–related peptide (CGRP) receptor antagonist (gepant)<sup>16,17</sup> that demonstrated efficacy, safety, and tolerability for preventive treatment of migraine in phase 2/3<sup>16</sup> and phase 3 (ADVANCE) trials in people with 4–14 monthly migraine days (MMDs).<sup>18</sup> In the ADVANCE trial, 10, 30, and 60 mg of atogepant once daily significantly reduced MMDs across the 12-week treatment period (primary endpoint) compared with placebo. In this study, we emphasized results from PROs that were selected as alpha-controlled secondary endpoints in the ADVANCE trial, in accordance with the US Food and Drug Administration (FDA) regulatory guidance.<sup>19</sup> These endpoints included changes from baseline in Migraine-Specific Quality-of-Life Questionnaire version 2.1 (MSQv2.1) Role Function–Restrictive (RFR) domain score at week 12 and mean monthly Activity Impairment in Migraine–Diary (AIM-D) Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores across the 12-week treatment period. We also presented results from pre-specified exploratory analyses of the MSQv2.1 RFR and AIM-D PDA and PI domains at other time points and other MSQv2.1 domains, total AIM-D score, and the Headache Impact Test

(HIT)–6 score. The primary research question was the effect of daily atogepant on health-related quality-of-life measures among patients with 4–14 migraine days per month.

## Methods

### Trial Design

Detailed methods of the ADVANCE trial have been published.<sup>18</sup> This multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial was conducted from December 14, 2018, to June 19, 2020, at 136 sites in the United States. Participants were randomized to receive placebo and atogepant (10, 30, or 60 mg) once daily (QD) at a 1:1:1 ratio. Randomization was stratified by previous exposure to a migraine prevention medication with proven efficacy. The randomization sequence was generated by an automated interactive web response system. Blinding was maintained by providing treatments in identical blister cards and masking treatment assignment from participants and site and sponsor personnel. The study included a 4-week baseline period, 12-week double-blind treatment period, and 4-week safety follow-up period. Participants were instructed to take study treatment once daily, orally, at approximately the same time each day.

### Participants

Eligible participants were adults aged 18–80 years with 4–14 MMDs in the 3 months before screening and 4–14 migraine days recorded in an electronic diary (eDiary) during the 28-day baseline run-in period. Additional inclusion criteria required ≥1-year history of migraine with or without aura consistent with a diagnosis according to the *International Classification of Headache Disorders, third edition (ICHD-3)*<sup>2</sup> and migraine onset before 50 years of age. Participants were excluded if they had a

current diagnosis of chronic migraine (CM), new persistent daily headache, trigeminal autonomic cephalalgia (e.g., cluster headache), or painful cranial neuropathy as defined by *ICHD-3*<sup>2</sup>;  $\geq 15$  monthly headache days (MHDs) on average across 3 months before visit 1 or during the 28-day baseline period; a history of inadequate response to  $>4$  medications (2 with different mechanisms of action) prescribed for preventive migraine treatment; use of opioids  $>2$  days per month, triptans or ergots  $\geq 10$  days per month, or simple analgesics (e.g., aspirin, nonsteroidal anti-inflammatory drugs, and acetaminophen)  $\geq 15$  days per month during the 3 months before screening or baseline period; or the use of barbiturates  $>2$  days per month in the 3 months before screening or any use within 30 days of screening.

## Outcome Measures

### Migraine-Specific Quality-of-Life Questionnaire Version 2.1

Participants completed the MSQ v2.1 through electronic tablet (eTablet) at study sites at baseline (treatment day 1) and at weeks 4, 8, and 12. The MSQ v2.1, a 14-item questionnaire designed to measure migraine-specific HRQoL over the past 4 weeks, has 3 domains.<sup>20,21</sup> The 7-item MSQ v2.1 RFR domain measures the degree to which migraine limits the performance of daily social and work-related activities. The 4-item MSQ v2.1 Role Function–Preventive (RFP) domain measures the degree to which migraine interrupts or prevents the performance of daily social and work-related activities. The 3-item Emotional Function (EF) domain assesses emotions associated with migraine. All MSQ v2.1 items use a 6-point ordinal scale with response options ranging from “none of the time” to “all of the time.” Raw domain scores were computed as a sum of item responses and rescaled to a 0–100 scale, based on the developer’s scoring scheme, where higher scores indicate better daily functioning (i.e., lesser effect of migraine) and positive changes in scores reflect improvement in quality of life. The MSQ v2.1 has been shown to be reliable, valid, and sensitive to changes in migraine with treatment.<sup>20,22</sup> The between-group minimally important difference (MID) for the MSQ-RFR is 3.2 points, MSQ-RFP is 4.6 points, and MSQ-EF is 7.5 points.<sup>23</sup> The meaningful within-group change for responder analyses is 5.0 points for the MSQ-RFR, 5.0–7.9 points for MSQ-RFP, and 8.0–10.6 points for MSQ-EF.<sup>18,23</sup> Change from baseline in MSQ-v2.1 RFR domain score at week 12 was a prespecified alpha-controlled secondary efficacy endpoint. Changes from baseline in the MSQ-v2.1 RFR domain score at weeks 4 and 8 and MSQ-v2.1 RFP and -EF domain scores at weeks 4, 8, and 12 were prespecified exploratory endpoints.

Per COVID-19–related protocol amendments, the MSQ v2.1 and HIT-6 at visit 7/week 12 were collected remotely by eTablet starting on 4/20/2020, according to the remote visit procedure. A total of 10 participants (1.1%) missed  $\geq 1$  PRO assessment at week 12 because of COVID-19.

### Activity Impairment in Migraine–Diary

Participants completed the AIM-D in eDiaries once daily throughout the entire study, including during the 4-week baseline period. The AIM-D is a novel, rigorously developed, and

psychometrically sound 11-item daily diary measure that assesses the effect of migraine.<sup>24</sup> The AIM-D has 2 domains: PDA (7 items) and PI (4 items). Validation studies for the AIM-D have been published.<sup>24</sup> Participants were asked to rate the level of difficulty experienced in the past 24 hours with PDA (i.e., difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly) and PI (i.e., difficulty walking, moving body, bending forward, and moving head) using a 6-point ordinal response scale ranging from “not difficult at all” to “I could not do it at all.” Three items also include response options of “I did not...” (e.g., “I did not have errands planned.”). The AIM-D was developed with similar questions and content for headache (HA) day and nonheadache (nHA) day items; the only difference is the instruction provided to the patient with “during your headache” indicated for the HA day version.

For both HA and nHA days, the daily AIM-D PDA domain score required availability of  $\geq 4$  item scores per day; otherwise, the domain score was considered missing. A raw daily AIM-D PDA score was calculated based on summation of scores for individual items 1–5, 10, and 11. Each of the 7 items had scores of 0–5, so that raw domain scores were 0–35. If the response category “I did not have errands, leisure or social, strenuous activities planned” (items 2, 4, and 5) was selected, the response was considered missing. The raw daily AIM-D PDA score was the sum of nonmissing item scores divided by the number of nonmissing items, given  $>50\%$  of items have responses, and then multiplied by 7. Raw daily scores were transformed to a 0–100 daily domain score by multiplying by 100 and dividing by the highest possible raw score (35). Higher scores indicate greater difficulty in performing daily activities. A similar approach was used for computing the raw daily score for the AIM-D PI domain and required that  $\geq 2$  item scores were available; if not, the domain score was considered missing. The raw daily AIM-D PI score (range: 0–20) was the sum of scores for individual items 6–9.

For both HA and nHA days, the daily total raw score (range: 0–55) was the sum of scores for individual items 1–11, if  $\geq 6$  items had nonmissing responses. When the response category “I did not have errands, leisure or social, strenuous activities planned” (items 2, 4, and 5) was selected, the response was considered missing. The daily total raw score was transformed to a 0–100 scale by multiplying by 100 and dividing by the highest possible raw score (55), with higher scores indicating worse activity impairment. Monthly AIM-D PDA and PI domain and total scores were the average of daily scores, calculated by summing nonmissing daily scores (HA and nHA days combined) and dividing by the number of nonmissing daily scores, provided there were  $\geq 14$  nonmissing daily scores (HA and nHA days combined) in the corresponding 28-day period; otherwise, the monthly total score was set to missing.

Changes from baseline in the mean monthly AIM-D PDA domain score and the mean monthly PI domain score across the 12-week treatment period were prespecified alpha-controlled secondary efficacy endpoints and have been previously

reported.<sup>18</sup> Changes from baseline in monthly PDA and PI domain scores of the AIM-D at weeks 1–4, 5–8, and 9–12 and in monthly AIM-D total score at weeks 1–4, 5–8, 9–12 and average across the 12-week treatment period were prespecified exploratory efficacy endpoints.

### Headache Impact Test-6

Participants completed the HIT-6 on an eTablet at study sites at baseline (day 1 of treatment) and at weeks 4, 8, and 12. The HIT-6 is a 6-item assessment used to measure the effect of headaches on normal daily life and ability to function on the job, at school, at home, and in social situations in the past 4 weeks.<sup>25,26</sup> Responses are based on frequency using a 5-point verbal response scale ranging from “never” to “always.” The HIT-6 total score is the sum of all responses, each of which is assigned a score ranging from 6 points (never) to 13 points (always). HIT-6 total scores range from 36–78 and are interpreted as little or no effect (score  $\leq 49$ ), some effect (50–55), substantial effect (56–59), and severe effect (60–78) due to headache, with higher scores indicating greater effect and lower scores indicating improvement.<sup>27</sup> The HIT-6 has been validated in people with episodic migraine (EM)<sup>28</sup> and in those with CM.<sup>28–30</sup> The between-group MID for HIT-6 in people with EM is  $-1.5$  points,<sup>31</sup> and the within-patient MID for responder analyses is a score reduction of 5.0 points.<sup>28,31–33</sup> Changes from baseline in HIT-6 total score at weeks 4, 8, and 12 and percentages of participants with  $\geq 5$ -point reduction in HIT-6 (responders) at weeks 4, 8, and 12 were prespecified exploratory endpoints.

### Statistical Analysis

All analyses were conducted on participants in the modified intent-to-treat (mITT) population with available data for each outcome measure and time point. The mITT population included all participants who received  $\geq 1$  dose of study drug, who had an evaluable baseline period of eDiary data, and who had  $\geq 1$  evaluable postbaseline 4-week period of eDiary data during the double-blind treatment period. Descriptive comparisons between the atogepant and placebo groups were reported as differences in change from baseline and corresponding odds ratios. Secondary endpoints of change from baseline in MSQ v2.1 RFR domain score at week 12 and changes from baseline in mean monthly AIM-D domain scores across the 12-week treatment period were analyzed using mixed models for repeated measures (MMRMs) that included the treatment group, visit, previous exposure to a migraine prevention medication (yes/no), and treatment group by visit as categorical fixed effects and baseline score and baseline-by-visit interaction as covariates. The overall type I error rate for multiple comparisons across the 3 atogepant doses and the secondary efficacy endpoints was controlled at the 0.05 level using a graphical approach with weighted-Bonferroni test procedure.<sup>34</sup> Within each dose, testing started from the primary endpoint, followed by testing of the secondary endpoints in a prespecified order.<sup>18</sup>

Continuous exploratory endpoints (i.e., changes from baseline in MSQ v2.1 domain scores, mean monthly AIM-D domain and total scores, and HIT-6 total scores) were analyzed using MMRM

models that included treatment group, visit, previous exposure to a preventive migraine medication (yes/no), and treatment group by visit as categorical fixed effects; and baseline score and baseline-by-visit interaction as covariates. Binary exploratory endpoints (i.e., percentage of participants with  $\geq 5$ -point improvement [decrease] from baseline in HIT-6 total score) were analyzed using a generalized linear mixed model that included treatment group, visit, previous exposure (yes/no) to a preventive migraine medication, and treatment group-by-visit interaction as categorical fixed effects; baseline value and baseline-by-visit interaction as covariates; and participants as random effects. Post hoc exploratory analyses of the proportions of participants reaching the within-group MID for each MSQ v2.1 domain used a similar generalized linear mixed model. *p* Values from the tests between each atogepant dose group and the placebo group are reported. Except for secondary efficacy endpoints, all analyses were performed at the nominal significance level, without adjusting for multiplicity.

### Standard Protocol Approvals, Registrations, and Participant Consents

All participating sites obtained approval from a local or central Institutional Review Board. The trial was conducted according to Good Clinical Practice and the Declaration of Helsinki. Participants provided written informed consent before enrollment. The study is registered with ClinicalTrials.gov (NCT03777059). The study protocol and statistical analysis plan have been published.<sup>18</sup>

### Data Availability

Clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. Data requests can be submitted at any time, and data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: [abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html](http://abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html).

## Results


### Participants and Baseline Characteristics

Of 910 participants randomized, 902 took  $\geq 1$  dose of trial treatment (safety population), and 873 were included in the mITT population (placebo,  $n = 214$ ; atogepant [10 mg],  $n = 214$ ; atogepant [30 mg],  $n = 223$ ; and atogepant [60 mg],  $n = 222$ ; Figure 1). Demographic and baseline characteristics are summarized in Table 1. In the mITT population, the mean (SD) age was 41.7 (12.3) years. Most participants were female (89%) and White (84%). Participants had a mean (SD) of 7.6 (2.4) MMDs and 8.7 (2.6) MHDs during the baseline period.

### Migraine-Specific Quality-of-Life Questionnaire Version 2.1

MSQ v2.1 domain scores at baseline were similar among treatment groups and were reflective of substantial to

**Figure 1** Participant Disposition



DBTP = double-blind treatment period; mITT = modified intent-to-treat; QD = once daily.

moderate effect on daily social and work-related activities with a mean MSQ-RFR score of 46, mean MSQ-RFP score of 61, and substantial emotional effect of migraine with a mean MSQ-EF score of 53 (Table 1). As previously reported,<sup>18</sup> the change from baseline in the MSQ-v2.1 RFR domain score at week 12 (secondary endpoint) demonstrated statistically significant and clinically meaningful (between-group difference exceeded MID of 3.2 points) improvements in the effect of migraine on daily social and work-related activities in all atogepant groups compared with placebo ( $p < 0.0001$  for all comparisons after multiplicity adjustment; Figure 2).

Analysis of exploratory MSQ v2.1 endpoints demonstrated nominally greater ( $p \leq 0.02$ ) improvements in all atogepant groups compared with placebo in MSQ-v2.1 RFR, MSQ-v2.1-RFP, and MSQ-v2.1-EF scores on the least-square mean difference (LSMD) scores from the earliest time point assessed (week 4) and throughout the 12-week double-blind treatment period (Figure 2). The LSMD between each atogepant group vs placebo in MSQ-v2.1 RFR, MSQ-v2.1-RFP, and MSQ-v2.1-EF scores achieved the between-group MID at all doses and time points evaluated, except for the EF domain in the 10 mg group at week 4 (Figure 2). Nominally greater proportions of participants in the atogepant groups than placebo had improvements in MSQ v2.1 scores that exceeded the established within-group MID (reflective of clinically meaningful improvement) for all 3 domains of the MSQ v2.1 at weeks 4, 8, and 12 ( $p \leq 0.04$ ), except for the RFP and EF domains at week 4 in the 10 mg group (Table 2).

### Activity Impairment in Migraine-Diary

At baseline, the mean AIM-D domain scores were similar among groups and reflected modest impairment in PDA (mean scores: 15–17) and PI (mean scores: 11–13; Table 1). As previously reported,<sup>18</sup> changes from baseline in mean monthly AIM-D PDA and PI scores across the entire 12-week double-blind treatment period (secondary endpoints) showed statistically significant improvement with atogepant (30 and 60 mg) compared with placebo ( $p \leq 0.002$  after multiplicity adjustment); the 10 mg group did not show statistically significant improvement compared with placebo (PDA,  $p = 0.086$ ; PI,  $p = 0.074$ ; Figure 3).

Analysis of exploratory AIM-D endpoints demonstrated nominally greater improvements in mean monthly AIM-D PDA and PI domain scores and total scores vs placebo in all atogepant groups over the first month of treatment (weeks 1–4,  $p \leq 0.012$ ) and for the 30 and 60 mg atogepant groups at weeks 5–8 ( $p \leq 0.040$ ) and 9–12 ( $p \leq 0.009$ ; Figure 3). Improvements in AIM-D scores increased with atogepant dose, with the largest improvements in AIM-D PDA, PI, and total scores consistently observed with 60 mg of atogepant at each time point (Figure 3).

### Headache Impact Test-6

The mean baseline HIT-6 total scores were similar among treatment groups and reflective of a severe effect of headaches (HIT-6 total score  $>60$ ; Table 1). All atogepant groups had nominal improvement ( $p \leq 0.006$ ) vs placebo in HIT-6 total

**Table 1** Demographics and Baseline Characteristics (Modified Intent-to-Treat Population)

	Atogepant				Total (N = 873)
	Placebo (n = 214)	10 mg QD (n = 214)	30 mg QD (n = 223)	60 mg QD (n = 222)	
Age, y	40.3 (12.9)	41.5 (12.0)	42.2 (11.7)	42.8 (12.3)	41.7 (12.3)
Female, n (%)	190 (88.8)	193 (90.2)	199 (89.2)	191 (86.0)	773 (88.5)
<b>Race, n (%)</b>					
White	188 (87.9)	176 (82.2)	181 (81.2)	184 (82.9)	729 (83.5)
Black or African American	22 (10.3)	32 (15.0)	37 (16.6)	27 (12.2)	118 (13.5)
Asian	2 (0.9)	2 (0.9)	1 (0.4)	7 (3.2)	12 (1.4)
Other or unknown	2 (0.9)	4 (1.9)	4 (1.8)	4 (1.8)	14 (1.6)
Ethnicity, non-Hispanic, n (%)	192 (89.7)	193 (90.2)	205 (91.9)	209 (94.1)	799 (91.5)
MMDs	7.5 (2.4)	7.5 (2.5)	7.9 (2.3)	7.8 (2.3)	7.6 (2.4)
MHDs	8.4 (2.6)	8.4 (2.8)	8.8 (2.6)	9.0 (2.6)	8.7 (2.6)
Monthly acute medication use days	6.5 (3.2)	6.6 (3.0)	6.7 (3.0)	6.9 (3.2)	6.7 (3.1)
<b>MSQ v2.1</b>					
	n = 213	n = 212	n = 222	n = 222	n = 869
Role Function–Restrictive	46.8 (19.7)	44.9 (21.4)	44.0 (19.6)	46.8 (20.4)	45.6 (20.3)
Role Function–Preventive	63.0 (21.9)	60.9 (23.4)	57.6 (24.0)	61.1 (24.2)	60.6 (23.4)
Emotional Function	54.0 (26.1)	53.5 (28.3)	49.9 (27.0)	53.3 (29.4)	52.6 (27.8)
<b>AIM-D</b>					
	n = 188	n = 191	n = 188	n = 192	n = 759
Performance of Daily Activities	15.2 (8.3)	15.5 (8.9)	16.9 (8.0)	15.9 (8.3)	15.9 (8.4)
Physical Impairment	11.2 (8.1)	11.7 (8.5)	13.0 (8.0)	11.6 (7.9)	11.9 (8.1)
Total score	13.6 (7.9)	14.0 (8.4)	15.4 (7.7)	14.2 (7.9)	14.3 (8.0)
<b>HIT-6 total score</b>					
	n = 213	n = 212	n = 223	n = 222	n = 870
	64.5 (4.6)	64.2 (5.3)	64.3 (4.7)	63.8 (5.5)	64.2 (5.0)

Abbreviations: AIM-D = Activity Impairment in Migraine–Diary; HIT-6 = Headache Impact Test–6; MHD = monthly headache day; MMD = monthly migraine day; MSQ v2.1 = Migraine-Specific Quality-of-Life Questionnaire version 2.1; QD = once daily. Data represent mean (SD) unless otherwise indicated.

score at the earliest time point assessed (week 4) and throughout the double-blind treatment period (exploratory endpoints; Figure 4A). The LSMD in change from baseline for atogepant vs placebo exceeded the between-group MID (1.5 points) in all atogepant groups at weeks 4, 8, and 12. Greater proportions of atogepant-treated participants vs placebo-treated participants were HIT-6 responders ( $\geq 5$ -point improvement from baseline) with all atogepant doses at all time points ( $p \leq 0.03$ ), with the exception of 30 mg of atogepant at week 4 ( $p = 0.07$ ; Figure 4B).

### Classification of Evidence


This study provides Class II evidence that daily atogepant is associated with improvements in health-related quality-of-life measures in patients with 4–14 migraine days per month. Further, it was associated with HRQoL improvement in the RFR domain of the MSQ v2.1 at week 12, a prespecified alpha-controlled secondary efficacy endpoint, for all 3 doses. In addition, atogepant is associated with reductions

(i.e., improvements) in other alpha-controlled secondary efficacy endpoints (e.g., AIM-D PI and PDA across 12 weeks of treatment) for the 30 and 60 mg doses. Although atogepant (10 mg) produced reductions on these outcomes, the differences were not uniformly significant.

## Discussion

Atogepant is a daily oral CGRP receptor antagonist for the preventive treatment of migraine. The ADVANCE trial compared 3 doses of atogepant with placebo for the preventive treatment of migraine in participants with 4–14 MMDs. A previous publication reported significant reductions in MMDs with corresponding significant increases in 50% responder rates, low discontinuation rates, and evidence of safety and tolerability for all 3 doses of atogepant vs placebo.<sup>18</sup> In addition to decreasing MMDs, reducing the effect of migraine on functioning in daily activities and improving overall HRQoL are important

**Figure 2** Change in MSQ v2.1 Scores



LS mean changes from baseline in MSQ v2.1 (A) RFR, (B) RFP, and (C) EF scores at weeks 4, 8, and 12. The LSMD for each atogepant group vs placebo was at least the between-group minimally important difference for each domain (MSQ-RFR: 3.2; MSQ-RFP: 4.6, and MSQ-EF: 7.5)<sup>23</sup> at each time point evaluated, with the exception of the EF domain at week 4 in the 10 mg group. Data for change from baseline MSQ v2.1 RFR at week 12 have been previously published.<sup>18</sup> EF = Emotional Function; LSM = least-square mean; LSMD = least-square mean difference; MSQ v2.1 = Migraine-Specific Quality-of-Life Questionnaire version 2.1; QD = once daily; RFP = Role Function-Preventive; RFR = Role Function-Restrictive.

**Table 2** Migraine-Specific Quality-of-Life Questionnaire Version 2.1 Responder Rates

	Placebo (N = 214)	Atogepant 10 mg QD (N = 214)	Atogepant 30 mg QD (N = 223)	Atogepant 60 mg QD (N = 222)
<b>Role Function–Restrictive domain (≥5-point improvement from baseline)</b>				
Week 4, n/N (%) <sup>a</sup>	135/205 (65.9)	159/208 (76.4)	177/217 (81.6)	179/217 (82.5)
Odds ratio vs placebo (95% CI) <sup>b</sup>		1.63 (1.03, 2.59)	2.22 (1.38, 3.57)	2.54 (1.57, 4.11)
p Value		0.036	0.001	<0.001
Week 8, n/N (%) <sup>a</sup>	146/202 (72.3)	162/187 (86.6)	179/208 (86.1)	178/206 (86.4)
Odds ratio vs placebo (95% CI) <sup>b</sup>		2.44 (1.43, 4.18) <sup>a</sup>	2.36 (1.40, 3.96)	2.43 (1.45, 4.07)
p Value		0.001	0.001	<0.001
Week 12, n/N (%) <sup>a</sup>	141/198 (71.2)	158/186 (84.9)	178/203 (87.7)	172/201 (85.6)
Odds ratio vs placebo (95% CI) <sup>b</sup>		2.22 (1.33, 3.69)	2.79 (1.66, 4.71)	2.44 (1.47, 4.03)
p Value		0.002	<0.001	<0.001
<b>Role Function–Preventive domain (≥5-point improvement from baseline)</b>				
Week 4, n/N (%) <sup>a</sup>	133/205 (64.9)	154/208 (74.0)	178/217 (82.0)	171/217 (78.8)
Odds ratio vs placebo (95% CI) <sup>b</sup>		1.49 (0.95, 2.33)	2.33 (1.45, 3.75)	2.00 (1.26, 3.16)
p Value		0.082	<0.001	0.003
Week 8, n/N (%) <sup>a</sup>	141/202 (69.8)	158/187 (84.5)	168/208 (80.8)	168/206 (81.6)
Odds ratio vs placebo (95% CI) <sup>b</sup>		2.35 (1.39, 3.98)	1.66 (1.02, 2.70)	1.75 (1.08, 2.84)
p Value		0.002	0.041	0.024
Week 12, n/N (%) <sup>a</sup>	140/198 (70.7)	153/186 (82.3)	170/203 (83.7)	169/201 (84.1)
Odds ratio vs placebo (95% CI) <sup>b</sup>		1.85 (1.10, 3.08)	2.04 (1.22, 3.42)	2.05 (1.23, 3.41)
p Value		0.019	0.007	0.006
<b>Emotional Function domain (≥8-point improvement from baseline)</b>				
Week 4, n/N (%) <sup>a</sup>	110/205 (53.7)	130/208 (62.5)	142/217 (65.4)	144/217 (66.4)
Odds ratio vs placebo (95% CI) <sup>b</sup>		1.49 (0.97, 2.30)	1.56 (1.01, 2.40)	1.80 (1.17, 2.78)
p Value		0.069	0.043	0.008
Week 8, n/N (%) <sup>a</sup>	109/202 (54.0)	137/187 (73.3)	149/208 (71.6)	138/206 (67.0)
Odds ratio vs placebo (95% CI) <sup>b</sup>		2.42 (1.51, 3.88)	2.15 (1.36, 3.39)	1.85 (1.18, 2.91)
p Value		<0.001	0.001	0.007
Week 12, n/N (%) <sup>a</sup>	112/198 (56.6)	129/186 (69.4)	148/203 (72.9)	137/201 (68.2)
Odds ratio vs placebo (95% CI) <sup>b</sup>		1.69 (1.07, 2.67)	1.92 (1.22, 3.03)	1.70 (1.09, 2.67)
p Value		0.025	0.005	0.020

Abbreviation: QD = once daily.

<sup>a</sup> Percentages are relative to the number of participants available for analysis at a specific time point in the modified intent-to-treat population.

<sup>b</sup> Analyses are based on a generalized linear mixed model for repeated measures. The model includes baseline as a covariate, previous exposure to migraine prevention medications (Y/N), treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms. Participants are included as random effects with unstructured covariance matrix in the model.



goals of migraine treatment from the perspectives of the patient, their family, employers, and payers.<sup>12,35,36</sup> Our results demonstrated significant improvements in PROs that assessed functioning in daily social and work-related activities and performance of daily activities, emotional effect, physical

impairment, and overall effect of headaches. Atogepant (30 and 60 mg) was associated with significant improvements in key alpha-controlled secondary endpoints (MSQ v2.1 RFR and AIM-D PDA and PI) over the 12-week treatment period; for the 10 mg dose, differences were statistically significant for MSQ





**Figure 3** Change in AIM-D Scores



**A. AIM-D performance of daily activities**



**B. AIM-D physical impairment**




**C. AIM-D total score**




LS mean changes from baseline in average monthly AIM-D (A) Performance of Daily Activities, (B) Physical Impairment, and (C) Total Score. Data for Performance of Daily Activities and Physical Impairment across the 12-week treatment period (months 1-3; secondary endpoint) have been previously published.<sup>18</sup> \**p* < 0.05 vs placebo. AIM-D = Activity Impairment in Migraine-Diary; LSMD = least-square mean difference; QD = once daily.

**Figure 4** Change in HIT-6 Score

**A.** HIT-6 total score: Change from baseline



**B.** HIT-6 responder rate



(A) Mean changes from baseline in HIT-6 total score. The between-group MID for HIT-6 is 1.5 points.<sup>31</sup> (B) Percentage of participants with ≥5-point improvement (responders) from baseline in HIT-6 total score. \**p* < 0.05 vs placebo. HIT-6 = Headache Impact Test-6; LSMD = least-square mean difference; QD = once daily.

v2.1 RFR but not for AIM-D among the alpha-controlled endpoints. Atogepant was also associated with nominal improvements in a series of exploratory endpoints as early as week 4.

For the MSQ v2.1, change in the RFR domain from baseline to week 12 was a key secondary endpoint, and earlier time points for the RFR domain and all time points for the RFP and

EF domains were exploratory endpoints. At week 12, each of the 3 atogepant groups demonstrated statistically significant and clinically meaningful improvement compared with placebo in the effect of migraine on daily social and work-related activities as measured by the MSQ v2.1 RFR domain. In addition, all 3 doses of atogepant achieved nominal improvements relative to placebo for all 3 MSQ v2.1 domains at weeks 4 and 8. All atogepant groups achieved the between-group MID vs placebo for the mean improvement in each MSQ v2.1 domain as early as week 4 and throughout the double-blind treatment period, except for the EF domain in the 10 mg group at week 4. The proportion of individuals with clinically meaningful improvements (i.e., responders with score improvement exceeding the within-group MID) in the MSQ v2.1 at week 12 was 85%–88% with atogepant 10–60 mg (vs 71% placebo) for the MSQ-RFR; 82%–84% (vs 71% placebo) for the MSQ-RFP; and 68%–73% (vs 57% placebo) for the MSQ-EF.

The AIM-D, a novel migraine-specific PRO, provides a daily diary-based assessment of performance of daily activities and reduction of physical impairment related to migraine. The 1-day recall period and daily diary format of the AIM-D are intended to minimize the bias that influences measures with longer recall intervals. The other validated daily diary PRO for migraine, the Migraine Physical Function Impact Diary,<sup>37</sup> was not available when study was planned, as exemplified by the 4-week recall interval of the MSQ v2.1 and the 3-month recall interval of the Migraine Disability Assessment Scale.<sup>15,38</sup> Both the MSQ v2.1 and the AIM-D contribute valuable information regarding the effect of migraine on functioning and performance of daily activities and therefore provide a more complete evaluation of migraine burden and treatment benefits. In particular, the AIM-D's assessment of difficulty in performance of daily activities and physical impairment provides complimentary measurement to the MSQ v2.1 RFR domain's evaluation of the frequency of migraine effect on daily social and work activities. The AIM-D PDA and PI domains and total score demonstrated good internal consistency reliability, test-retest reliability, construct validity, known-groups validity, and responsiveness. In the ADVANCE trial, changes from baseline in mean monthly AIM-D PDA and PI domain scores across the 12-week treatment period were alpha-controlled secondary endpoints, and PDA and PI domain scores at monthly time points and AIM-D total scores were exploratory endpoints. Atogepant (30 and 60 mg) demonstrated statistically significant improvements from baseline compared with placebo in mean monthly AIM-D PDA and PI scores across the 12-week treatment period; the 10 mg group also showed improvement in both domains, but the mean change was not significantly different from placebo. The 30 and 60 mg atogepant groups had numerically greater improvements than the placebo group in exploratory endpoints of AIM-D PDA, PI, and total scores across weeks 1–4 that were maintained through the end of the trial.

Changes from baseline in HIT-6 total score (exploratory endpoint) showed that each atogepant dose was associated with nominal and clinically meaningful reductions in

headache effect vs placebo at first assessment (week 4) and throughout the double-blind treatment period. The HIT-6 responder rate (proportion of individuals  $\geq 5$ -point improvement) at week 12 was 63%–65% across atogepant dose groups compared with 52% with placebo.

Previous studies have demonstrated that preventive migraine treatments from various drug classes, including oral preventives and injectable CGRP-targeted monoclonal antibodies (mAbs), improved HRQoL and functioning and reduced headache effect and disability in people with EM.<sup>39–43</sup> Multiple placebo-controlled clinical trials of CGRP-targeted mAbs in participants with EM demonstrated significant and clinically meaningful improvements in the MSQ v2.1 RFR, RFP, and EF domains and in HIT-6 scores with mAbs vs placebo for up to 6 months of treatment.<sup>41–46</sup> Methodological differences limit cross-study comparisons. However, all CGRP-targeted treatments were associated with improvements in MSQ v2.1 domains and HIT-6 total scores. This is the first randomized controlled trial to assess treatment benefits using AIM-D.

This trial has strengths and limitations. This rigorously designed double-blind placebo-controlled trial used established validated PRO instruments that measure changes in functional ability, activity impairment, and headache effect over time. The trial was not powered for key secondary endpoints, including the change from baseline in MSQ v2.1 RFR at week 12 and AIM-D PDA and PI across the 12-week treatment period, although these were prespecified alpha-controlled secondary efficacy endpoints. The MSQ v2.1 RFR measure has been included in the US labeling for migraine preventives; however, the HIT-6 has not.<sup>47</sup> The National Institute of Neurological Disorders and Stroke highly recommends both the MSQ v2.1 and HIT-6 for headache studies.<sup>48</sup> The MSQ v2.1 and HIT-6 have 4-week recall periods, raising recall bias as a potential limitation. There are other recall-based PROs, which were not included or available during the study, including the Migraine Functional Impact Questionnaire.<sup>49</sup> By contrast, as a daily diary, the AIM-D has a same-day recall period. The AIM-D, which was specifically constructed based on FDA guidance for PRO development<sup>19</sup> for use in clinical trials of migraine treatments, provides some unique insights into the effects of atogepant on migraine-related activity impairment. The lack of statistically significant changes in AIM-D scores in the 10 mg dose group is surprising, considering the significant changes with MSQ v2.1 and HIT-6. AIM-D scores are averaged across the month for HA and nHA days. In an EM study, by definition, participants do not have headaches on most days, truncating the potential range of AIM-D scores and creating a potential for floor effects. The baseline AIM-D total score for the overall population was 14.3 (range: 13.6–15.4), on a scale with a maximum value of 100. In addition, the benefits of atogepant might be greater on HA days than on nHA days. Combining HA days and nHA days may generate an AIM-D metric that is less sensitive than an HA day measure, particularly for a lower dose of a preventive treatment. The AIM-D has not been compared directly with other diary data or scales. Finally, the

duration of follow-up was only 12 weeks; some PRO outcomes may continue to improve beyond 12 weeks, so longer studies could be helpful.<sup>50</sup> Future work should separately score HA and nHA days to distinguish the benefits of atogepant on ictal and interictal burden. Only participants with 4–14 MMDs were included in the ADVANCE trial, but a phase 3 atogepant trial in people with CM is ongoing (NCT03855137).

In conclusion, atogepant demonstrated significant and clinically meaningful improvements in functioning in daily social and work-related activities and performance of daily activities and reductions in emotional effect, physical impairment, and overall effect of headaches. Improvements were observed at the earliest assessment point (4 weeks) and throughout the 12-week double-blind treatment period for the 30 and 60 mg doses. In addition, atogepant (10 mg), the lowest dose assessed, improved MSQ-v2.1 domain and HIT-6 scores. The early onset of improved functioning is important to patients and payers.<sup>35,36</sup> Together, these results reinforce the beneficial effects of atogepant as a promising new treatment for the prevention of migraine.

## Acknowledgment

Writing and editorial assistance was provided to the authors by Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and was funded by AbbVie. The opinions expressed in this article are those of the authors. The authors received no honorarium/fee or other form of financial support related to the development of this article.

## Study Funding

Allergan, now AbbVie, sponsored the study; contributed to the design; and participated in the analysis and interpretation of data and in writing, reviewing, and approval of the final version. No honoraria or payments were made for authorship.

## Disclosure

R.B. Lipton has received research support from the NIH, the FDA, and the National Headache Foundation. He serves as a consultant and advisory board member and has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Dr. Reddy's Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from Wolff's Headache, 8th edition (Oxford University Press, 2009), and Informa. He holds stock/options in Biohaven, Manistee, and Ctrl M. P. Pozo-Rosich reports the following conflicts within the past 18 months: consulting: AbbVie, Eli Lilly, Lundbeck, Medscape, Novartis, and Teva; research grants: EraNet Neuron, FEDER RISC3CAT, la Caixa foundation, Instituto Investigación Carlos III, AbbVie, Novartis, and Teva; and has received funding for clinical trials from AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva. She is the founder of midolordecabeza.org. She does not own stocks in any pharmaceutical company. A.M. Blumenfeld has served on advisory boards for AbbVie, Aeon, Alder, Allergan, Amgen, Axsome,

Biohaven, Impel, Lundbeck, Lilly, Novartis, Revance, Teva, Theranica, and Zoscano; has received funding for speaking from AbbVie, Allergan, Amgen, Biohaven, Lundbeck, Lilly, and Teva; has served as a consultant for AbbVie, Alder, Allergan, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, and Theranica; received grant support from Allergan and Amgen; and is a contributing author for AbbVie, Allergan, Amgen, Biohaven, Lilly, Novartis, and Teva. J. Stokes and P. Gandhi are employees of AbbVie and may hold AbbVie stock. Y. Li and L. Severt were employees of AbbVie during this study and may hold AbbVie stock. L. Creutz declares no disclosures relevant to the manuscript. D.W. Dodick reports the following conflicts: consulting: Amgen, Atria, Cerecin, Cooltech, Ctrl M, Allergan, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, AYYA Biosciences, and Revance; honoraria: Teva (speaking), Amgen (speaking), Eli Lilly (speaking), Lundbeck (speaking), Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, Synapse, MJH Lifesciences, Miller Medical Communications, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Research Support: Department of Defense, NIH, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient-Centered Outcomes Research Institute (PCORI). Stock Options/Shareholder/Patents/Board of Directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (options), Theranica (options), Second Opinion/Mobile Health (options), Epien (options/board), Nocira (options), Matterhorn (shares/board), Ontologics (shares/board), King-Devick Technologies (options/board), Precon Health (options/board), AYYA Biosciences (options), Axon Therapeutics (options/board), Cephalgia Group (options/board), and Atria Health (options/employee). National Center for Biotechnology Information (2022). PubChem Patent Summary for WO-2011123456-A1. Retrieved February 17, 2022 from [pubchem.ncbi.nlm.nih.gov/patent/WO-2011123456-A1](https://pubchem.ncbi.nlm.nih.gov/patent/WO-2011123456-A1) (Botulinum toxin dosage regimen for chronic migraine prophylaxis). Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

## Publication History

Received by *Neurology* September 1, 2021. Accepted in final form September 28, 2022. Submitted and externally peer reviewed. The handling editor was Rebecca Burch, MD.

## Appendix Authors

Name	Location	Contribution
<b>Richard B. Lipton, MD</b>	Albert Einstein College of Medicine, Bronx, NY	Designed and conceptualized study; analyzed and interpreted the data; and drafted and revised the article for intellectual content

Continued

## Appendix (continued)

Name	Location	Contribution
<b>Patricia Pozo-Rosich, MD, PhD</b>	Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona; Headache Research Group, VHIR, Departament de Medicina, Universitat Autònoma de Barcelona, Spain	Revised the article for intellectual content
<b>Andrew M. Blumenfeld, MD</b>	Headache Center of Southern California, Carlsbad	Revised the article for intellectual content
<b>Ye Li, PhD*</b>	AbbVie, Madison, NJ *Employee during this study	Revised the article for intellectual content
<b>Lawrence Severt, MD*</b>	AbbVie, Madison, NJ *Employee during this study	Revised the article for intellectual content
<b>Jonathan Stokes, MBA</b>	AbbVie, Madison, NJ	Analyzed and interpreted the data; revised the article for intellectual content
<b>Lela Creutz, PhD*</b>	Peloton Advantage, an OPEN Health company, Parsippany, NJ *Employee during manuscript development	Drafted and revised the article under the guidance of the authors
<b>Pranav Gandhi, PhD</b>	AbbVie, Madison, NJ	Designed study; analyzed and interpreted the data; and drafted and revised the article for intellectual content
<b>David W. Dodick, MD</b>	Department of Neurology, Mayo Clinic, Scottsdale, AZ; Atria Institute, New York	Revised the article for intellectual content

## References

- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1859-1922. doi:10.1016/S0140-6736(18)32335-3.
- Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018; 38:1-211.
- Goadsby PJ, Evers S. International Classification of Headache Disorders—ICHD-4 alpha. *Cephalalgia*. 2020;40(9):887-888. doi:10.1177/0333102420919098.
- Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. *Headache*. 2018;58(4):496-505. doi:10.1111/head.13281.
- Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. *Headache*. 2021;61(1):60-68. doi:10.1111/head.14024.
- Mannix S, Skalicky A, Buse DC, et al. Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. *Health Qual Life Outcomes*. 2016;14(1):143. doi:10.1186/s12955-016-0542-3.
- Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. *Neurol Clin*. 2019;37(4):631-649. doi:10.1016/j.ncl.2019.06.001.
- Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. *Cephalalgia*. 2011; 31(7):837-850. doi:10.1177/0333102411398400.
- Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). *Cephalalgia*. 2011;31(3):301-315. doi:10.1177/0333102410381145.
- Leonardi M, Raggi A, Bussone G, D'Amico D. Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. *Headache*. 2010;50(10):1576-1586. doi:10.1111/j.1526-4610.2010.01770.x.
- Freitag FG. The cycle of migraine: patients' quality of life during and between migraine attacks. *Clin Ther*. 2007;29(5):939-949. doi:10.1016/j.clinthera.2007.05.008.
- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59(1): 1-18. doi:10.1111/head.13456.
- Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. *Cephalalgia*. 2020;40(10):1026-1044. doi:10.1177/0333102420941839.
- Management of migraine (with or without aura). National Institute for Health and Care Excellence. 2021. pathways.nice.org.uk/pathways/headaches/management-of-migraine-with-or-without-aura. Accessed February 10, 2021.
- McGinley JS, Houts CR, Nishida TK, et al. Systematic review of outcomes and endpoints in preventive migraine clinical trials. *Headache*. 2021;61(2):253-262. doi: 10.1111/head.14069.
- Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. *Lancet Neurol*. 2020;19(9):727-737. doi:10.1016/S1474-4422(20)30234-9.
- Qulipta (atogepant) tablets [package insert]. AbbVie, 2021.
- Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. *N Engl J Med*. 2021;385(8):695-706. doi:10.1056/nejmoa2035908.
- Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of Health and Human Services, Food and Drug Administration, 2009. fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed April 13, 2021.
- Cole JC, Lin P, Rupnow MFT. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. *Qual Life Res*. 2007;16(7):1231-1237. doi:10.1007/s11136-007-9217-1.
- Rendas-Baum R, Bloudek LM, Maglante GA, Varon SF. The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. *Qual Life Res*. 2013;22(5):1123-1133. doi:10.1007/s11136-012-0230-7.
- Speck RM, Shalhoub H, Wyrwich KW, et al. Psychometric validation of the role function restrictive domain of the Migraine Specific Quality-of-Life Questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. *Headache*. 2019;59(5):756-774. doi:10.1111/head.13497.
- Cole JC, Lin P, Rupnow MF. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version. *Cephalalgia*. 2009;29(11):1180-1187. doi:10.1111/j.1468-2982.2009.01852.x.
- Lipton RB, Gandhi P, Stokes J, et al. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: the Activity Impairment in Migraine Diary. *Headache*. 2022;62(1):89-105. doi: 10.1111/head.14229.
- Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. *Qual Life Res*. 2003;12(8):963-974. doi:10.1023/a:1026119331193.
- Houts CR, Wirth RJ, McGinley JS, et al. Content validity of HIT-6 as a measure of headache impact in people with migraine: a narrative review. *Headache*. 2020;60(1): 28-39. doi:10.1111/head.13701.
- Martin M, Blaisdell B, Kwong JW, Bjorner JB. The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. *J Clin Epidemiol*. 2004; 57(12):1271-1278. doi:10.1016/j.jclinepi.2004.05.004.
- Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. *Cephalalgia*. 2011;31(3): 357-367. doi:10.1177/0333102410379890.
- Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M. Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. *Health Qual Life Outcomes*. 2014;12(1):117. doi:10.1186/s12955-014-0117-0.
- Houts CR, McGinley JS, Wirth RJ, Cady R, Lipton RB. Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study. *Qual Life Res*. 2021;30(3):931-943. doi:10.1007/s11136-020-02668-2.
- Smelt AF, Assendelft WJ, Terwee CB, Ferrari MD, Blom JW. What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. *Cephalalgia*. 2014;34(1):29-36. doi:10.1177/0333102413497599.
- Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. *Neurology*. 2019;92(19): e2250-e2260. doi:10.1212/wnl.00000000000007452.
- Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB. Determining thresholds for meaningful change for the Headache Impact Test (HIT-6) total and item-specific scores in chronic migraine. *Headache*. 2020;60(9):2003-2013. doi:10.1111/head.13946.
- Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. *Stat Med*. 2009;28(4):586-604. doi:10.1002/sim.3495.
- Smelt AFH, Louter MA, Kies DA, et al. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. *PLoS One*. 2014;9(6):e98933. doi:10.1371/journal.pone.0098933.
- Diener HC, Ashina M, Durand-Zaleski I, et al. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. *Cephalalgia*. 2021;41(3):279-293. doi:10.1177/0333102421989247.
- Hareendran A, Mannix S, Skalicky A, et al. Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine: the migraine physical function impact diary (MPFID). *Health Qual Life Outcomes*. 2017;15(1):224. doi:10.1186/s12955-017-0799-1.
- Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based

- measure in a population sample of migraine sufferers. *Pain*. 2000;88(1):41-52. doi:10.1016/s0304-3959(00)00305-5.
39. Garcia-Monco JC, Foncea N, Bilbao A, Velasco IRd, Gomez-Beldarrain M. Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. *Cephalalgia*. 2007;27(8):920-928. doi:10.1111/j.1468-2982.2007.01367.x.
  40. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. *Clin Ther*. 2009;31(3):542-559. doi:10.1016/j.clinthera.2009.03.020.
  41. Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. *Cephalalgia*. 2018;38(6):1026-1037. doi:10.1177/0333102418759786.
  42. Buse DC, Lipton RB, Hallstrom Y, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. *Cephalalgia*. 2018;38(10):1622-1631. doi:10.1177/0333102418789072.
  43. Ford JH, Ayer DW, Zhang Q, et al. Two randomized migraine studies of galcanezumab: effects on patient functioning and disability. *Neurology*. 2019;93(5):e508-e517. doi:10.1212/wnl.00000000000007856.
  44. Ayer DW, Skljarevski V, Ford JH, Nyhuis AW, Lipton RB, Aurora SK. Measures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled phase 2b trial with galcanezumab. *Headache*. 2018;58(8):1225-1235. doi:10.1111/head.13383.
  45. Shibata M, Nakamura T, Ozeki A, Ueda K, Nichols RM. Migraine-Specific Quality-of-Life Questionnaire (MSQ) version 2.1 score improvement in Japanese patients with episodic migraine by galcanezumab treatment: Japan phase 2 study. *J Pain Res*. 2020;13:3531-3538. doi:10.2147/jpr.s287781.
  46. Silberstein SD, Cohen JM, Yang R, et al. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials. *J Headache Pain*. 2021;22(1):2. doi:10.1186/s10194-020-01212-4.
  47. *Emgality [package insert]*. Eli Lilly and Company, 2019.
  48. National Institute of Neurological Disorders and Stroke. *Summary of core supplemental—highly recommended recommendations: headache CDEs*. National Institute of Neurological Disorders and Stroke, 2020. [commondataelements.ninds.nih.gov/sites/nindscde/files/Doc/Headache/CDEStartupResource\\_Headache.pdf](https://commondataelements.ninds.nih.gov/sites/nindscde/files/Doc/Headache/CDEStartupResource_Headache.pdf). Accessed November 11, 2020.
  49. Haywood K, Potter R, Froud R, et al. Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. *BMJ Open*. 2021;11(11):e043242. doi:10.1136/bmjopen-2020-043242.
  50. Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF. Patient-reported outcomes from a 1-year, real-world, head-to-head comparison of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. *J Prim Care Community Health*. 2020;11:215013272095993. doi:10.1177/2150132720959936.

# Neurology<sup>®</sup>

**Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes  
in the Randomized, Double-blind, Phase 3 ADVANCE Trial**

Richard B. Lipton, Patricia Pozo-Rosich, Andrew M. Blumenfeld, et al.

*Neurology* 2023;100:e764-e777 Published Online before print November 17, 2022

DOI 10.1212/WNL.0000000000201568

**This information is current as of November 17, 2022**

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.



<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/100/8/e764.full">http://n.neurology.org/content/100/8/e764.full</a>
<b>References</b>	This article cites 45 articles, 3 of which you can access for free at: <a href="http://n.neurology.org/content/100/8/e764.full#ref-list-1">http://n.neurology.org/content/100/8/e764.full#ref-list-1</a>
<b>Citations</b>	This article has been cited by 1 HighWire-hosted articles: <a href="http://n.neurology.org/content/100/8/e764.full##otherarticles">http://n.neurology.org/content/100/8/e764.full##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Clinical trials</b> <a href="http://n.neurology.org/cgi/collection/all_clinical_trials">http://n.neurology.org/cgi/collection/all_clinical_trials</a> <b>Class II</b> <a href="http://n.neurology.org/cgi/collection/class_ii">http://n.neurology.org/cgi/collection/class_ii</a> <b>Clinical trials Randomized controlled (CONSORT agreement)</b> <a href="http://n.neurology.org/cgi/collection/clinical_trials_randomized_controlled_consort_agreement">http://n.neurology.org/cgi/collection/clinical_trials_randomized_controlled_consort_agreement</a> <b>Migraine</b> <a href="http://n.neurology.org/cgi/collection/migraine">http://n.neurology.org/cgi/collection/migraine</a> <b>Outcome research</b> <a href="http://n.neurology.org/cgi/collection/outcome_research">http://n.neurology.org/cgi/collection/outcome_research</a> <b>Quality of life</b> <a href="http://n.neurology.org/cgi/collection/quality_of_life">http://n.neurology.org/cgi/collection/quality_of_life</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

